Tc 99m ethylenedicysteine deoxyglucose - CellPoint
Alternative Names: (99m)Tc ethylenedicysteine-deoxyglucose; 99m-Tc-EC-DG; 99mTC ethylene dicysteine deoxyglucose; 99mTc ethylenedicysteine N-acetyl glucosamine; 99mTc-oncardia; EC-deoxyglucose-Tc-99m; Ethylenedicysteine-deoxyglucose-Tc-99m; Oncardia-Tc-99m; Oncardia®; Tc 99m EC glucosamine; Tc 99m ethylenedicysteine glucosamine; Tc-99m-Oncardia; Technetium TC 99m ECDG; Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose; Technetium-99m-labeled ethylenedicysteine-glucosamine; Technetium-99m-labelled-OncardiaLatest Information Update: 04 Nov 2017
At a glance
- Originator CellPoint LLC
- Developer CellPoint; University of Chicago
- Class Diagnostic conjugates; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Ionising radiation emitters; Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Lung cancer; Myocardial ischaemia
Highest Development Phases
- Phase III Lung cancer
- Phase II Myocardial ischaemia; Non-small cell lung cancer
- No development reported Head and neck cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Diagnosis) in USA (IV, Injection)
- 03 Aug 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Diagnosis) in Canada (IV)
- 01 Feb 2015 Tc 99m ethylenedicysteine deoxyglucose is still in phase II trials for Myocardial ischaemia (Diagnosis) in USA